We performed a prognostic risk score signature containing DNMT2, NSUN3, NSUN6, YBX1, and NOP2 using a LASSO Cox regression model according to the minimum criterion to evaluate the prognosis value of m5C methylation modification on individual CM patients accurately (Figure 4(a)). This evidence concerns the gene NOP2 and cutaneous mastocytosis.